Is Fabino Enter overvalued or undervalued?

As of 8 August 2025, the valuation grade for Fabino Enter has moved from risky to expensive, indicating a shift in perception regarding its financial health. The company is currently assessed as overvalued. Key ratios include a PE Ratio of 5.46, an EV to EBIT of 6.27, and a ROE of 3.13%.
In comparison to its peers, Fabino Enter's PE Ratio of 5.46 is notably lower than Sun Pharma's 33.19 and Divi's Lab's 68.04, yet it still falls into the expensive category, suggesting that despite its lower valuation metrics, the market has priced it higher than its fundamental performance would justify. Additionally, the stock has underperformed relative to the Sensex, with a year-to-date return of -20.97% compared to the Sensex's 2.20%, reinforcing the notion that Fabino Enter may not be a favorable investment at its current price.